Alector (ALEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually for shareholder participation.
Proxy materials, including the annual report and proxy statement, are available online or by request.
Voting matters and shareholder proposals
Election of three directors: Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D.
Ratification of Ernst & Young, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Board recommends voting "FOR ALL NOMINEES" and "FOR" both other proposals.
Board of directors and corporate governance
Board nominees include individuals with medical and scientific backgrounds.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alector
- Board recommends approval of all proposals, emphasizing governance, risk, and ESG.ALEC
Proxy filing28 Apr 2026 - ABC platform delivers potent, safe brain-targeted therapies with strong clinical and market potential.ALEC
Corporate presentation26 Mar 2026 - Biotech firm seeks to raise up to $400M for neurodegenerative R&D via flexible securities offering.ALEC
Registration Filing12 Mar 2026 - ABC platform delivers potent brain-targeted therapies, with IND and phase 1 trials imminent.ALEC
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Revenue and expenses declined in 2025, with a net loss of $142.9M and cash runway through 2027.ALEC
Q4 202525 Feb 2026 - Late-stage neurodegeneration programs progress with pivotal data and strong pharma partnerships.ALEC
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference3 Feb 2026 - Lead FTD drug nears pivotal data as pipeline advances and GSK partnership drives commercialization.ALEC
Cantor Global Healthcare Conference 20253 Feb 2026 - ABC platform enables efficient brain delivery, advancing therapies for neurodegenerative diseases.ALEC
Status Update3 Feb 2026 - Late-stage neurodegeneration trials progress, strong $503M cash runway supports outlook.ALEC
Q2 20242 Feb 2026